
Brain Cell Transplant Slows Rare Neurodegenerative Disease
In a small study of eight patients with ALSP, replacing dysfunctional microglia with normal microglia using traditional bone marrow transplantation (BMT) halted the progression of ALSP and improved neurologic function.
'The critical next step is to validate these results in a larger clinical trial, which is already underway,' principal investigator Bo Peng, PhD, professor, Institute for Translational Brain Research, Fudan University in Shanghai, told Medscape Medical News .
The study was published online on July 10 in Science .
From Mice to Men
ALSP is a rare, progressive neurological disease with an average age of onset of 43 years and an average life expectancy of only 3-5 years after symptoms begin. There is no cure and there are few treatments.
ALSP is caused by mutations in the colony-stimulating factor 1 receptor gene (CSF1R), which is critical to development and survival of microglia. Mutations in this gene lead to microglial dysfunction and reduced numbers of these key brain immune cells.
In earlier work, Peng and his team developed mouse models of ALSP which exhibit hallmark features of the disease including reduced numbers of microglia, myelin abnormalities, axonal swelling and motor impairments, and cognitive decline.
To test whether microglial replacement could alter disease progression in mice with ALSP, the investigators tested two approaches: traditional BMT and microglia replacement by BMT (Mr BMT), a protocol that combines pharmacological depletion of microglia with traditional BMT.
Both approaches effectively replaced mutant microglia with wild-type counterparts and successfully reversed myelin defects, axonal swellings, and motor and cognitive impairments in the animals.
To translate this to the clinic, they performed traditional BMT in eight patients with ALSP. Although traditional BMT alone typically does not achieve efficient Mr in healthy brains, the inherent CSF1R deficiency in patients with ALSP creates a 'competitive disadvantage' for the recipient's resident microglia, allowing traditional BMT to achieve effective replacement, the researchers explained in their paper.
In the 2 years following Mr, MRI and clinical evaluations indicated 'halted disease progression, preserved motor function, and stabilized cognitive abilities,' the team reported. By contrast, untreated patients with ALSP exhibited rapid worsening of brain pathology over a shorter time frame.
The findings in these eight patients also provide a 'mechanistic explanation' for a prior clinical case in which an individual with ALSP, initially misdiagnosed with adult-onset metachromatic leukodystrophy, exhibited long-term stabilization after traditional BMT.
'While the path forward is active with the ongoing trial, traditional BMT becoming a widely accessible 'clinic-ready' standard treatment for ALSP is still estimated to be several years away, contingent upon successful trial outcomes, long-term safety data, and subsequent regulatory approvals,' Peng told Medscape Medical News .
Beyond ALSP
Peng also said Mr 'holds significant theoretical promise' for treating other neurological diseases involving microglial dysfunction, including Alzheimer's disease (AD).
'Genome-wide association studies have identified TREM2 as one of the major risk genes in sporadic AD. TREM2 mutation may cause or accelerate the progression of AD. In a 2020 paper in Cell Reports , we proposed that we can replace the TREM2 -mutated microglia with TREM2 -normal cells to treat this disease,' Peng added.
In a Science perspective , Siling Du, PhD, and Jonathan Kipnis, PhD, with the Brain Immunology and Glia Center, Washington University in St Louis congratulated Peng and colleagues for demonstrating in humans that 'correcting a microglial gene defect through cell replacement can arrest disease progression.'
Du and Kipnis agreed that the potential implications of this research extend beyond ALSP.
For example, a recent study demonstrated that microglial replacement can also rescue pathology in a mouse model of Krabbe disease, a monogenic neurodegenerative disorder caused by mutations in the gene encoding galactosylceramidase.
In addition, traditional BMT has also been shown to arrest disease progression in a mouse model of Rett syndrome — a severe neurodevelopmental condition caused by loss-of-function mutations in the gene encoding methyl-CpG binding protein 2.
'Together, these findings highlight the therapeutic potential of microglial replacement in modifying the course of monogenic neurological diseases,' Du and Kipnis said.
Looking ahead, they said it will be important to establish the optimal donor cell source to achieve 'scalable, safe, and durable microglial replacement.'
'It is also not yet clear whether the systemic toxicity caused by pretransplant conditioning can be minimized without compromising engraftment. Future strategies must strike a balance between replacement efficiency, systemic toxicity, and the functional competence of engrafted cells,' they wrote.
'Moving forward, it may ultimately become possible to reprogram the brain's immune landscape from within and find the best microglial replacement approach not only for microgliopathies but for a spectrum of neurological diseases,' Du and Kipnis concluded.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
2 hours ago
- Medscape
What Factors Influence a Patient's Success on GLP-1s?
Longer treatment duration, not having diabetes, and using semaglutide were among the factors associated with better weight reduction over 12 months among patients taking GLP-1 receptor agonists (RA), a cohort study suggested. 'Treatment responses differ among patients receiving GLP-1 RAs, and the weight fluctuations and associated factors following [their] use have not been adequately characterized,' Linong Ji, MD, of Peking University People's Hospital in Beijing, China, told Medscape Medical News . The findings, published online in Diabetes, Obesity and Metabolism , 'may provide novel insights into weight fluctuations after GLP-1 RA treatment in a real-world setting,' he said, potentially advancing the development of individualized strategies for patients. 'Corroborates Other Studies' Researchers conducted a real-world, single-center, retrospective study of 679 patients with overweight or obesity who initiated GLP-1 RA treatment between November 2022 and October 2024. At baseline, participants had a mean age of 37 years, and 31% were men. The mean BMI was 33.4, and 21% were diagnosed with diabetes. The GLP-1 RAs used in the study included semaglutide (Ozempic), liraglutide (Victoza), lixisenatide (Lyxumia), beinaglutide (Yishengtai), exenatide (Bydureon), dulaglutide (Trulicity), and PEG-loxenatide (Fulaimei). All were available for participants with both type 2 diabetes (T2D) and overweight/obesity. For participants with overweight/obesity but without T2D, only Ozempic or Victoza were routinely prescribed, with off-label documentation and informed consent. Weight measurements were collected during in-person clinic visits, and weight fluctuation curves were stratified into three phenotypes — Successful Weight Reduction, Remaining Stable, and Weight Regain. Subsequently, the association between potential influencing factors and weight fluctuations was estimated by univariate and multivariate logistic regression. Subgroup analyses were performed in participants with obesity, prediabetes, and in those using liraglutide or semaglutide. Researchers found significant differences in the duration of GLP-1 RA treatment across groups at the 3-, 6-, and 12-month follow-ups. The Successful Weight Reduction group had a significantly longer duration of GLP-1 RA treatment than the Remaining Stable group and a longer duration at both the 6- and 12-month follow-ups than the Weight Regain group. Diabetes status also showed group differences. At both the 3- and 6-month follow-ups, the proportion of patients with T2D in the Successful Weight Reduction group was lower than in the Remaining Stable group. Types of GLP-1 RAs varied between groups, and at the 3- and 6-month follow-ups, the Successful Weight Reduction group was more likely to have initiated treatment with semaglutide than the Remaining Stable group. Patients with a longer duration of GLP-1 RA treatment (odds ratio [OR], 1.014) and higher Homeostasis Model Assessment of Beta-Cell Function levels (OR, 4.912) were more likely to achieve successful weight reduction at the 12-month follow-up. Nondiabetic status (OR, 2.176) and using semaglutide (OR, 2.138) were associated with successful weight reduction at the 6-month follow-up. In addition, a higher percentage of body fat in both men (OR, 3.990) and women (OR, 2.266) was associated with successful weight reduction. The weight regain group had a higher baseline estimated glomerular filtration rate than the Successful Weight Reduction group and the Remaining Stable group at 3-month follow-up, especially among participants with prediabetes. Ji said this finding surprised him. Patients with obesity often exhibit a state of renal hyperfiltration, characterized by elevated renal plasma flow and glomerular filtration rate, which can be reversed by weight reduction. The finding suggests that patients with renal hyperfiltration might be less likely to experience durable weight reduction, Ji said. 'However, few studies have revealed similar observations. Therefore, further validations and investigations are still needed for this finding.' Furthermore, the team found a positive nonlinear association of serum creatinine with successful weight reduction at 12 months — a finding that will also require additional investigations to examine the mechanism underlying the association. Overall, Ji concluded that while longer duration of GLP-1 RA treatment using semaglutide, nondiabetic status, and higher percentage of body fat might be associated with better weight reduction, 'basal metabolic rate, skeletal muscle mass, muscle mass of the abdomen and limbs, and serum creatinine were nonlinearly associated with the probability of successful weight reduction.' Randy Seeley, MD, Henry King Ransom Endowed Professor of Surgery, Internal Medicine, and Nutritional Sciences at the University of Michigan School of Medicine, Ann Arbor, Michigan, and director of the National Institutes of Health-funded Michigan Nutrition Obesity Research Center, told Medscape Medical News , 'The main results of the study agree with what the field has already seen. Although it is a relatively small study, it corroborates other larger studies,' said Seeley, who was not involved in the study. This work was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project. Ji reported receiving fees for lecture presentations and for consulting from AstraZeneca, Merck, Metabasis, MSD, Novartis, Eli Lilly and Company, Roche, Sanofi-Aventis, and Takeda. Seeley reported that his lab has worked with both Novo and Lilly (and others trying to enter the space), and he has also served as a paid consultant for both of those companies (and others trying to enter the space).


Medscape
3 hours ago
- Medscape
DLBCL: FDA Rejects BLA for Second-Line Glofitamab Combo
The FDA rejected a supplemental Biologics License Application (sBLA) for glofitamab-gxbm (Columvi, Genentech) in combination with gemcitabine and oxaliplatin for the second-line treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who are not candidates for autologous stem cell transplant. A complete response letter from the FDA stated that Genentech's phase 3 STARGLO trial did not provide sufficient evidence to support the proposed second-line DLBCL indication for the T cell engaging bispecific antibody in the US, according to a Genentech statement. However, a conditional FDA approval in the third-line or greater setting remains in place. FDA's decision regarding second-line glofitamab aligns with an advisory committee vote in May, which cited a lack of US patient representation in the trial. The Oncologic Drugs Advisory Committee (ODAC) voted 8-1 against recommending approval, as reported by Medscape Medical News . The FDA asked for ODAC review over concerns that nearly half of the STARGLO participants were from Korea, Taiwan, and China, with most of the remaining participants coming from Europe and Australia. Only 25 US patients were included. Outcomes among Asian vs non-Asian patients differed, with a strong trend toward worse overall survival (OS), rates in White patients and patients from Europe and the US, despite a strong overall 0.59 hazard ratio for OS. Similar trends were observed for progression-free survival and complete response rates. At the time, the FDA said the low US enrollment 'limits the agency's ability to assess the applicability of the study results to a US patient population,' and cited additional concerns regarding comparator drugs used in the trial, according to meeting documents. 'While we are disappointed with this outcome, we remain confident in the data supporting the value of Columvi for US patients who have relapsed following initial treatment, and its key role as monotherapy in the third-line setting,' Genentech's Chief Medical Officer and head of Global Product Developments, Levi Garraway, MD, PhD, said in the company statement regarding the sBLA rejection. 'We are committed to bringing Columvi to more people living with lymphoma and are actively exploring its potential in additional treatment settings, including as frontline therapy.' 'For patients with this aggressive form of lymphoma, effective treatment after relapse is paramount,' added Jeremy Abramson, MD, the principle STARGLO investigator and director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, Boston. Abramson stressed that in the STARGLO trial, the glofitamab combination therapy improved OS, which 'could have a positive impact for patients earlier in their treatment journey.' The regimen is currently approved for this indication in more than 35 countries. It is approved in more than 60 countries for third-line or greater treatment of DLBCL, including in the US where the FDA granted accelerated approval in 2023. STARGLO was also intended as a post-marketing confirmatory study to support conversion of the accelerated approval to full approval, Genentech noted. Results were published in 2024 in The Lancet, and 2-year follow-up data showing sustained overall improvements in the primary and secondary endpoints were presented at 2025 American Society of Clinical Oncology Meeting. Genentech said the regimen is currently being investigated in combination with other agents as a first-line treatment for DLBCL in the phase 3 SKYGLO study.
Yahoo
3 hours ago
- Yahoo
Engineering Beyond Earth - How Carbon Fiber Composites Are Recasting Spacecraft Architecture
The space carbon fiber composites market is poised for growth due to increased satellite launches, reusable launch systems, and commercial space activities. Key opportunities arise in next-gen spacecraft needing lightweight, durable materials. The U.S. and China lead innovation, driving demand in satellites and rocket components. Space Carbon Fiber Composites Market Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The "Space Carbon Fiber Composites - Global Strategic Business Report" report has been added to Beyond Earth: How Carbon Fiber Composites Are Recasting Spacecraft Architecture The global market for Space Carbon Fiber Composites was estimated at US$451.2 Million in 2024 and is projected to reach US$571.9 Million by 2030, growing at a CAGR of 4.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Space Carbon Fiber Composites market. The growth in the global space carbon fiber composites market is driven by several factors including increased satellite launches, the commercialization of low-Earth orbit, and demand for reusable launch systems. As launch economics shift toward cost-per-kilogram metrics, carbon composites offer compelling performance advantages that translate into reduced fuel consumption, enhanced payload capacity, and faster vehicle turnaround. The NewSpace movement-characterized by private-sector-led innovation-is also accelerating composite adoption through prototyping flexibility, agile manufacturing, and performance-driven design is occurring across multiple dimensions. New resin systems with lower cure temperatures and outgassing properties are being developed to support out-of-autoclave and in-space fabrication techniques. Thermoplastic composites are gaining attention for their recyclability, damage tolerance, and weldability. Additive manufacturing using carbon fiber-reinforced filaments is enabling the production of complex components with reduced lead times and on-demand customization. Nanocomposites using carbon nanotubes (CNTs) and graphene are also under investigation to enhance electrical conductivity, mechanical performance, and multi-functionality of space trajectories include the integration of structural health monitoring systems, multifunctional composites with embedded antennas or heat pipes, and adaptive materials capable of shape change or energy storage. As the commercial space ecosystem matures-with players entering satellite servicing, space mining, and orbital manufacturing-carbon fiber composites will remain foundational to enabling lightweight, scalable, and resilient space structures. The interplay of material science, mission engineering, and orbital sustainability is positioning space-grade composites as a vital component in the future of extraterrestrial Makes Carbon Fiber Composites Vital for Space Applications and Mission Reliability?Carbon fiber composites have become indispensable in space applications due to their unique combination of high strength-to-weight ratio, dimensional stability, and resistance to extreme temperatures and radiation. These advanced materials, typically composed of carbon fibers embedded in polymer matrices such as epoxy, cyanate ester, or polyimide resins, are used extensively in satellite structures, launch vehicle fairings, propulsion components, antenna reflectors, and modular space habitats. Compared to traditional metals like aluminum and titanium, carbon fiber composites enable substantial weight reduction-an essential factor in improving payload efficiency and lowering launch carbon fiber composites offer enhanced radiation shielding and reduced outgassing, which are crucial for protecting sensitive electronic equipment and ensuring thermal control in spacecraft. These performance characteristics make them ideal for next-generation spacecraft where modularity, reusability, and sustainability are Applications and Vehicle Platforms Are Driving Demand for Carbon Fiber Composites in Space?Satellites-both commercial and defense-grade-represent a significant segment for space carbon fiber composite demand. Satellite buses, solar panel arms, instrument platforms, and booms are now predominantly manufactured using composite structures to reduce weight while maintaining rigidity and resistance to mechanical stress during launch and orbit operations. With the miniaturization trend in satellite design, composites enable compact yet robust frames that support high-resolution imaging, communication arrays, and propulsion vehicles and rockets are another major use case. The shift toward reusable rockets by companies like SpaceX, Blue Origin, and Rocket Lab is accelerating composite integration in fuel tanks, interstage structures, and fairings. Carbon composite cryogenic tanks, for example, reduce mass while maintaining the necessary thermal insulation and containment performance for liquid hydrogen and oxygen. NASA and private aerospace players are also leveraging carbon-carbon and ceramic matrix composites (CMCs) for heat shields and nozzle components that must withstand the extreme re-entry applications include space stations, lunar habitats, and in-space manufacturing platforms where lightweight, modular construction is critical. Composites are also playing a role in robotic arms, deployable structures, and additive manufacturing feedstocks. Space tourism and commercial spaceflight ventures are anticipated to further fuel demand for carbon fiber composite cabins, interior panels, and occupant safety systems optimized for suborbital and orbital Regions and Organizations Are Leading in Composite Innovation for Space Use?The United States leads the global market for space carbon fiber composites, supported by a strong ecosystem of aerospace manufacturers, defense contractors, and composite material suppliers. Companies like Northrop Grumman, Boeing, Lockheed Martin, and SpaceX rely on advanced composite parts supplied by Hexcel Corporation, Toray Advanced Composites, and Solvay. NASA-s Composites for Exploration Upper Stage Structures (CEUSS) program and the Space Launch System (SLS) development have significantly advanced U.S. composite design and qualification protocols for deep space is also a significant player, with the European Space Agency (ESA), Airbus Defence and Space, and Thales Alenia Space driving demand for high-performance composite structures. The EU-s Horizon programs and Clean Sky initiatives are funding composite R&D aimed at reducing environmental impact and enhancing aerospace competitiveness. Japan, through Mitsubishi Electric and the Japan Aerospace Exploration Agency (JAXA), maintains a strong position in carbon fiber production and satellite systems. Meanwhile, China is rapidly scaling up domestic composite manufacturing for its Long March launch vehicles and Beidou satellite program, while India-s ISRO is expanding its composite fabrication capabilities for its PSLV and Gaganyaan supply chains are witnessing vertical integration, with composite part manufacturers collaborating closely with resin formulators and aerospace primes to ensure flight qualification and mission customization. International regulatory harmonization, particularly under ISO and ECSS (European Cooperation for Space Standardization), is facilitating cross-border cooperation in composite design, testing, and Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Advanced Composites Solutions, Aernnova Aerospace S.A., Arris Composites, Boston Materials LLC, Collins Aerospace and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Satellites Application segment, which is expected to reach US$306.9 Million by 2030 with a CAGR of a 3.8%. The Launch Vehicles Application segment is also set to grow at 4.6% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $122.9 Million in 2024, and China, forecasted to grow at an impressive 7.3% CAGR to reach $116.0 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments: Application (Satellites Application, Launch Vehicles Application, Deep Space Exploration Application) End-Use (Commercial End-Use, Research End-Use, Defense End-Use) Key Attributes: Report Attribute Details No. of Pages 274 Forecast Period 2024 - 2030 Estimated Market Value in 2024 451.2 Million Forecasted Market Value by 2030 571.9 Million Compound Annual Growth Rate 4.0% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Space Carbon Fiber Composites - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Satellite Launch Frequencies Drive Demand for Lightweight, High-Strength Materials Adoption in Payload Structures and Satellite Antennas Promotes Material Optimization Use in Space Launch Vehicles for Fairings, Interstage Sections, and Fuel Tanks Expands Scope Increased Demand for Thermal Resistance in Deep Space Applications Boosts R&D Miniaturization and Cubesat Proliferation Promote Use of Thin-Wall Composite Structures Integration of Radiation-Resistant Resins Improves Material Survivability in Harsh Conditions Private Sector Entry Into Spaceflight Drives Innovation in Cost-Effective Composite Manufacturing Adoption in Structural Panels for Manned Missions Strengthens Human-Rated Component Use Development of Automated Fiber Placement (AFP) Technologies Enhances Production Throughput Collaboration Between Space Agencies and Aerospace Suppliers Accelerates Composite Design Focus on Mission Durability and Weight Optimization Enhances Market Potential Emergence of Green Composite Manufacturing Supports Sustainable Satellite Development Expansion of In-Orbit Servicing and Space Tourism Promotes New Use Cases Growth in Hypersonic Research and Spaceplane Development Creates Additional Demand Shift Toward Additive Manufacturing With Composite Filaments Opens Lightweighting Opportunities Military and Defense Spending on Space Reconnaissance Expands Procurement of Carbon Structures Standardization of Aerospace-Grade Carbon Materials Improves Interoperability Across Programs Rising Participation of Commercial Launch Providers Drives Composite Supply Chain Scaling Partnerships With Universities and Material Science Startups Accelerate New Resin Systems Market for Reusable Launch Systems Encourages Tougher, Fatigue-Resistant Composite Solutions FOCUS ON SELECT PLAYERS |Some of the 37 companies featured in this Space Carbon Fiber Composites market report include: Advanced Composites Solutions Aernnova Aerospace S.A. Arris Composites Boston Materials LLC Collins Aerospace Hexcel Corporation Hexion Inc. Huayuan Advanced Materials Co., Ltd. Hyosung Advanced Materials Lee Aerospace, Inc. Materion Corporation MCCFC (Mitsubishi Chemical Carbon Fiber & Composites) Nippon Graphite Fiber Co., Ltd. Premium AEROTEC GmbH SGL Carbon SE Solvay S.A. Spirit AeroSystems Inc. Teijin Limited Toray Advanced Composites Toray Industries, Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Space Carbon Fiber Composites Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio